Remove 2022 Remove Key account management Remove Leads Remove Pharma
article thumbnail

The Imperative for KAM in Pharma

PM360

Over the past decade, macro trends in healthcare have pushed life sciences companies to pursue increasingly sophisticated key account management (KAM) strategies and capabilities to provide unique offerings and value. How should leading pharma companies respond? The Importance of Large, Organized Customers.

article thumbnail

Largest global clinical site hires all-female key leaders in Europe

European Pharmaceutical Review

She was medical lead at SIBAmed GmbH for four years. This will help to maximise on cross-selling opportunities, providing a seamless and customer-centric experience to Velocity’s pharma and CRO partners. She has 20 years’ experience in business development and key account management in the clinical trials arena.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

A matter of access

Star OUTiCO

I’ve worked in the pharmaceutical industry full-time for 24 years across a variety of roles but mostly within Leadership and Market Access, and latterly heading up Key Account Management at Boehringer-Ingelheim. Our pharma partners see this as one of the most valuable assets we have to offer.

article thumbnail

7 commercial, sales, and marketing predictions for 2023

pharmaphorum

In 2022, life sciences companies have been hard at work breaking down silos to better serve patients and healthcare professionals (HCPs). Leading companies will empower their teams to act quickly, compliantly, and with a unified view of the HCP.”. Marketing data will surpass health data as a leading signal for pharma advertisers.

article thumbnail

Quality first: How pharma can meet injectables demand while staying compliant

Pharmaceutical Technology

According to the GlobalData report Contract Injectable Packaging Trends in the Bio/Pharma Industry , more than half (55%) of FDA drug approvals in 2021 were accounted for by injectables. In addition, in 2022, non-new molecular entity (NME) injectables approvals were the highest they have been for the last decade.

Pharma 52